COMP <GO>
EXEL vs JNJ // EV/EBITDA & P/E VALUATION
Exelixis Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: EXEL 12
— JNJ 2
▲ EV/EBITDA & P/E VALUATION LEADER: EXEL
LAST: $69.39 (+4.82%) • MKT CAP: $16.40B
valuation
18.4x
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
valuation
18.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EXEL VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EXEL | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 67.90% | +28.10 | EXEL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 35.10% | 25.50% | +9.60 | EXEL | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 18.4x | 18.5x | -0.10 | EXEL | /valuation <GO> |
| Free Cash Flow Yield | 5.34% | 2.97% | +2.37 | EXEL | /fcf-yield <GO> |
| Operating Margin | 37.60% | 34.70% | +2.90 | EXEL | /operating-margins <GO> |
| Net Profit Margin | 33.70% | 28.50% | +5.20 | EXEL | /net-margins <GO> |
| Revenue Growth (YoY) | 7.00% | 6.00% | +1.00 | EXEL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 16.64 | 5.59 | +11.05 | EXEL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | EXEL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 7.20% | -0.40 | EXEL | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 81.7 | 60.4 | +21.30 | EXEL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.96 | 1.08 | -0.12 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 19.5x | 23.0x | -3.50 | EXEL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $16.40B | $662.49B | -$646.09B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EXEL REV | JNJ REV | EXEL GROSS % | JNJ GROSS % | EXEL FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.32B | $94.19B | 96.4% | 67.9% | $875.8M | $19.70B |
| FY 2024 | $2.17B | $88.82B | 96.5% | 69.1% | $671.5M | $19.84B |
| FY 2023 | $1.83B | $85.16B | 44.0% | 44.0% | $251.0M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EXEL // BETA 0.96
JNJ // BETA 1.08